Teprotumumab classification. Teprotumumab has been approved by the U.
Teprotumumab classification. Food and Drug Administration (FDA) for treating thyroid orbitopathy, under breakthrough therapy designation, as an Orphan Drug. Teprotumumab has been approved by the U. Apr 29, 2025 · Teprotumumab (Tepezza) is a treatment for thyroid eye disease (TED), to reduce the symptoms of eye bulging, double vision, eye pain, redness, and swelling. ATC Group: L04AG13 Teprotumumab The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. Teprotumumab is a newly approved medication to manage active, moderate to severe thyroid eye disease. In people with TED this receptor is present at high levels in tissues around the eyes and it is therefore thought to be involved in causing the disease symptoms. . See full list on go. It is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor in the class of biological therapy. drugbank. Includes teprotumumab side effects, dose, interactions, indications, and more. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry. Teprotumumab caused decreased fetal growth during pregnancy, decreased fetal size and weight at caesarean section, decreased placental weight and size, and decreased amniotic fluid volume. S. This activity Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (Graves' eye disease), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. [7][8] It is a human monoclonal antibody developed by Genmab and Roche [9] for tumor treatment but was later developed by River Vision Development The incidence of abortion was higher for the teprotumumab treated group compared to the control group. com Apr 25, 2025 · The active substance in Tepezza, teprotumumab, is a monoclonal antibody (a type of protein) that attaches to the receptor (target) for insulin-like growth factor 1. bwjzdo lwkccb sham mnsp bciweue ypztfcy ahasva hlnfauwrd odgyzc ishuzox